Form 4 Intellia Therapeutics, For: Jun 17 Filed by: Verwiel Frank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Stifel on Intellia Therapeutics (NTLA): 'Positive Ph.3 HELIOS-B data this morning validates the NTLA-2001 approach'
June 24, 2024 12:15 PM EDTStifel analyst Dae Gon Ha reiterated a Buy rating and $80.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "Positive Ph.3 HELIOS-B data this morning validates the NTLA-2001 approach and with the Ph.3 MAGNITUDE study ongoing, should be seen... More
Baird on Intellia Therapeutics (NTLA): 'we anticipate enthusiasm will wane'
June 24, 2024 9:49 AM EDTBaird analyst Jack Allen reiterated a Neutral rating and $24.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "No change to outlook on competitor's clinical data. This morning, Alnylam (ALNY, not covered) announced positive top-line results from the HELIOS-B study of their... More
